The Sub-Saharan Africa Regional Partnership (SHARP) for Mental Health Capacity-Building Scale-Up Trial: Study Design and Protocol
Abstract
Background:
Depression is a leading cause of death and disability worldwide, including in low- and middle-income countries (LMICs). Depression often coexists with chronic medical conditions and is associated with worse clinical outcomes. This confluence has led to calls to integrate mental health treatment with chronic disease care systems in LMICs. This article describes the rationale and protocol for a trial comparing the clinical effectiveness and cost-effectiveness of two different intervention packages to implement evidence-based antidepressant management and psychotherapy into chronic noncommunicable disease (NCD) clinics in Malawi.
Methods:
Using constrained randomization, the Sub-Saharan Africa Regional Partnership (SHARP) for mental health capacity building will assign five Malawian NCD clinics to a basic implementation strategy via an internal coordinator, a provider within the chronic care clinic who champions depression services by providing training, supervision, operations, and reporting. Another five clinics will be assigned to depression services implementation via an internal coordinator along with an external quality assurance committee, which will provide a quarterly audit of intervention component delivery with feedback to providers and the health management team.
Results:
The authors will compare key implementation outcomes (fidelity to intervention), clinical effectiveness outcomes (patient health), and cost-effectiveness and will assess characteristics of clinics that may influence uptake and fidelity.
Next steps:
This trial will provide key information to guide the Malawi Ministry of Health in scaling up depression management in existing NCD settings. The SHARP trial is anticipated to substantially contribute to enhancing both mental health treatment and implementation science research capacity in Malawi and the wider region.
HIGHLIGHTS
•
The burden of depression in low- and middle-income countries is substantial; thus, developing effective strategies for integrating mental health treatment into chronic disease care systems is crucial.
•
The Sub-Saharan Africa Regional Partnership clinical trial will compare the outcomes of two approaches for implementing depression screening and treatment into standard care in noncommunicable disease clinics.
•
One implementation package will involve only an internal coordinator and another an internal coordinator along with an external quality assurance committee, which will conduct quarterly audits of intervention component delivery.
•
Assessments of implementation outcomes and cost-effectiveness of each package are anticipated to enhance both mental health treatment and implementation science research capacity in Malawi and the broader region.
Editor’s Note: In partnership with Milton L. Wainberg, M.D., Psychiatric Services is publishing protocols to address the gap between global mental health research and treatment. These protocols present large-scale, global mental health implementation studies soon to begin or under way. Taking an implementation science approach, the protocols describe key design and analytic choices for delivery of evidence-based practices to improve global mental health care. This series represents the best of our current science, and we hope these articles inform and inspire.
Depression is a leading cause of death and disability worldwide, including in low- and middle-income countries (LMICs) (1–3), with mortality rates of those affected, and not limited to patients with severe cases or who commit suicide, twice the rates in the general population (4). Despite these high societal, economic, and quality-of-life costs, those with depressive illness do not receive the same quality of general medical health care as people in the general population (4). Depression often coexists with increasingly prevalent chronic medical conditions in LMICs, such as hypertension and diabetes, and is associated with worse clinical outcomes of these comorbid conditions (5). This confluence has led to calls for integrating mental health treatment with expanding chronic disease care systems in LMICs (6, 7).
Despite the high prevalence and negative consequences of depression, most sub-Saharan African health systems have severely limited capacity to treat patients with depression. The median number of mental health professionals per 100,000 population in sub-Saharan African nations is less than one-fiftieth of that in the United States (8, 9), and more than three-quarters of those needing mental health treatment in these countries have no access to such care (10). This enormous mental health treatment gap demands a focus on task-sharing models that equip nonspecialists, such as primary care providers or community workers, with the means to address common mental health problems (10).
Strong evidence exists that both psychosocial counseling and antidepressant treatment are effective for managing depression and that they can be effectively delivered by general practitioners and community workers in research trials conducted in LMICs. For example, with psychosocial counseling, the “Friendship Bench” intervention—a culturally adapted, manualized, problem-solving, therapy-focused counseling intervention developed by Chibanda and colleagues (11) in Zimbabwe—utilizes lay health care workers or community members to deliver structured problem-solving therapy and effectively manage common mental disorders in primary health care settings (11, 12).
Similarly, algorithm-based care for depression (ABCD), a task-sharing depression treatment model that uses antidepressants, has a strong evidence base and high potential for scale-up and impact in low-resource settings. ABCD enables nonpsychiatric staff to manage depression effectively in clinical settings through antidepressant prescription using algorithms that guide dose titration depending on systematically assessed depression symptom severity and adverse effects of antidepressants. The availability and demonstrated efficacy of low-cost antidepressants in low-resource settings make approaches such as ABCD part of a highly promising strategy that efficiently integrates depression treatment into existing clinical care systems. We have conducted research for >10 years on the effectiveness of ABCD in both primary (13, 14) and HIV (15) care and more recently have demonstrated the safety, feasibility, and acceptability of ABCD in Africa (16). Other research has demonstrated the effectiveness of ABCD integration into HIV care in Uganda (17) and its integration into chronic disease care in high-income countries (18, 19).
Despite this strong evidence that ABCD can be effectively integrated into primary clinical care, scale-up of such services in low-resource settings is impeded by a lack of knowledge of the level of resource investment required to achieve acceptable fidelity to the intervention and effectiveness in real-world practice. Implementation science research to identify optimal implementation strategies is therefore critical to advance scale-up efforts. The Sub-Saharan Africa Regional Partnership (SHARP) for mental health capacity building aims to address this knowledge gap. Our objective is to expand mental health treatment in the region by implementing high-quality research; developing research and implementation capacity among governmental, academic, and nongovernmental partners; rand enhancing dialogue between those partners.
One part of SHARP is a scale-up study whose goal is to compare the implementation and effectiveness outcomes of two implementation packages for the integration of depression screening and treatment into standard care in noncommunicable disease (NCD) clinics in Malawi. This clinical environment is ripe for scaling up. The Malawi Ministry of Health (MOH) has strongly prioritized an expansion of depression treatment in its chronic disease clinics (20, 21). However, in a setting with limited resources and few mental health professionals, and where the country’s first psychiatrist in a generation completed medical training only 2 years ago, the most efficient way to implement such a treatment model is unclear. A key knowledge gap impeding the scale-up of Friendship Bench and the ABCD is the level of resource investment required to achieve acceptable fidelity and effectiveness in various clinics.
Accordingly, we will conduct a randomized controlled trial in several clinics to determine the best way to integrate evidence-based depression treatment into NCD clinics in Malawi. We will compare depression treatment involving a basic implementation package with an enhanced implementation package. These two implementation packages were informed by previous implementation science strategies involving external and internal facilitation to implement evidence-based mental health treatment programs in clinical care (22–24). They were adapted through consultation with the Malawi MOH to be most relevant to the clinical context in Malawi. The basic implementation package will involve identifying an internal coordinator (IC) who is one of the full-time onsite providers at the clinic, reflecting an approach often used by the Malawian public health system. The IC provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinical priorities. The enhanced implementation package will consist of the IC together with an external quality assurance committee (EQAC), a scalable and feasible package based on previous work in Malawi with HIV patients. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol and provide high-level support in implementing the treatment program through clinical expertise and limited onsite presence. Key challenges informed our study design and are listed in Table 1.
| Challenge | Design solution | Advantage |
|---|---|---|
| Engaging policy makers | Inclusion of a policy maker as a principal investigator (in Malawi) and as coinvestigators (Malawi, Tanzania) | Immediate feedback and input to make study questions and outcomes relevant to policy decision making |
| Implementing Friendship Bench counseling | Weighed options of lay health workers, peers, and others to train peer patients for Friendship Bench | Involvement of peers more sustainable and consistent with original Friendship Bench model |
| Trained trainers within Malawi | Have assembled a cadre of trainers who can continue to train counselors throughout the country after study completion | |
| Ensuring consistent medication supply | Tasking internal coordinator (IC); monthly reporting; intervention with central medical stores by policy makers; intervention with DHMTs to prioritize stocking antidepressants; Friendship Bench as alternative | More consistent supply of amitriptyline and fluoxetine |
| Lack of trained personnel and increased clinical workload | Tasking the IC with training other clinicians, nurses, data clerks, and other relevant clinical staff at their NCD clinics (strategy of “training everyone”) | Ensures coverage for screening and treatment of depression across clinicians, which can improve sustainability, builds training capacity of ICs, and builds clinical capacity of other clinicians |
| Ensuring policy relevance of findings | Ministry of Health (MOH) official is a principal investigator; engage multiple stakeholders | Findings more likely to be actionable for the MOH and relevant to policy goals |
| Ensuring findings are generalizable to all of Malawi | Selected noncommunicable diseases clinics housed in 10 hospitals distributed across the country in each of the three regions in Malawi (northern, central, and southern) | Provides information relevant to each region |
| Constrained 1:1 randomization | Avoids imbalance among regions and in the number of providers, number of patients per month, quality of engagement in NCD service delivery, quality of engagement in initial study site visit, and quality of record-keeping | |
| Creating allocation concealment mechanism | Randomization will be masked until 3 months after trial launch | Avoids initial start-up support being affected by knowledge of study arm; at 3 months, the first EQAC visits will occur, revealing allocation |
| Feasibility | Use of a mental health mastercard that mirrors the already used NCD medical chart mastercard (each of which will be available for each clinic visit) | Familiarity of card will increase likelihood of implementation |
| The basic implementation strategy, with its identification of a local coordinator with these responsibilities, was designed to reflect an approach often used in the Malawian public health system by which new programs are rolled out | Familiarity of approach will increase likelihood of implementation | |
| The enhanced implementation package includes all the elements of the basic implementation package, with the addition of an EQAC modeled on a successful Malawian HIV care approach consisting of quarterly visits of each facility to audit paperwork, review service delivery, and provide feedback and recommendations to the coordinator, the facility leadership, and the MOH | Basing the package on a previously successful implementation strategy in Malawi will increase likelihood of successful implementation | |
| Blinding in clinic-level interventions precludes personnel from being masked to treatment allocationb | To assess fidelity, we will use aggregation of deidentified clinical records on all patients | Data will be analyzed in blinded fashion |
| To assess remission, we will use PHQ-9 self-report measures by patients who will not be told their treatment allocation by research staff and are unlikely to be aware of the allocation | Data will be analyzed in blinded fashion | |
| To assess hypertension and diabetes outcomes, we will use objective measures unaffected by blinding | Data will be analyzed in blinded fashion |
a
Advantages were conferred by the design solution. EQAC, external quality assurance committee; DHMT, District Health Management Team; NCD, noncommunicable disease; PHQ-9, Patient Health Questionnaire–9.
b
In a clinic-level intervention, most personnel may not be masked to treatment allocation. The clinical coordinator, Friendship Bench counselors, and facility leadership cannot be masked to the allocation once the EQAC site visits have started, because all of these individuals will meet with or receive reports from the external committee. Patients cannot be explicitly blinded to allocation. Research assistants (i.e., the research outcome assessors) are each permanently based at one site and are present in the clinic daily; it is likely not feasible to coordinate or conduct the external committee site visits without the local research assistant’s awareness.
Objectives and Hypotheses
This article details a protocol for a scale-up study that compares the clinical effectiveness and cost-effectiveness of two different implementation packages in achieving integration of depression management into NCD clinics in Malawi: a basic implementation package (IC only) versus IC and EQAC (IC+EQAC).
Our hypotheses are as follows. Compared with providers at clinics receiving the basic implementation package (IC only), providers at clinics receiving the enhanced implementation package (IC+EQAC) will deliver depression treatment with greater fidelity to the intervention. Compared with patients receiving care at clinics with the basic IC-only package, patients receiving care at clinics with the IC+EQAC package will be more likely to achieve depression remission at 6 and 12 months. Compared with patients receiving care at clinics with the IC-only package, patients receiving care at clinics with the IC+EQAC package will be more likely to have well-controlled hypertension and diabetes at 6 and 12 months.
Methods
Overall Study Design
Our goal is to compare the clinical effectiveness and cost-effectiveness of two approaches for integrating depression screening and treatment into 10 NCD clinics in Malawi by implementing a clinical trial with 1:1 constrained randomization by clinic, such that five clinics receive the IC-only package and five receive the IC+EQAC package. This constrained design will ensure balance of group-level prognostic factors across the two compared arms, allowing us to avoid imbalance due to geographical region, number of providers, number of patients per month, quality of engagement in NCD service delivery, quality of engagement in initial study site visit, and quality of record-keeping. We will assess outcomes for those receiving care at clinics through either the IC-only or the IC+EQAC package, as indicated by providers’ fidelity to depression treatment; patients’ depression remission at 3, 6, and 12 months; and patients’ well-controlled hypertension and diabetes at 3, 6, and 12 months. We will also compare the cost-effectiveness of the two packages in achieving depression remission and NCD control.
Settings and Site Selection
The trial focuses on secondary-level district hospitals, the setting for the recent establishment of NCD clinics nationwide. After an assessment of key contextual and structural characteristics of each clinic, including organizational readiness for change, management support, patient panel size, patient demographic characteristics, and storage facilities for medications, we selected 10 hospital-based NCD clinics representing the three main regions of Malawi: northern (two clinics), central (four clinics), and southern (four clinics). We will enroll 116 patients from each of the 10 clinics, yielding a total sample of 1,160 patients.
Target Population and Selection Criteria
We will enroll patients meeting the following criteria in the research outcome interview component of the trial: eligible participants will be ages 18–65 years; be current or new patients receiving care for hypertension, diabetes, or both from a participating NCD clinic; and have elevated depressive symptoms (Patient Health Questionnaire–9 [PHQ-9] score ≥5). The PHQ-9 screens for and monitors depressive symptom severity (25) and has been validated in Malawi (26). Patients will be excluded if they have a history of bipolar or psychotic disorder or exhibit emergent threat of self-harm.
A research assistant will evaluate all NCD patients for potential eligibility. Data from all patients, regardless of whether they are enrolled in the research outcome interview component, will be included in the primary fidelity outcomes because the data come from aggregation of deidentified clinical records of all patients.
Study Procedures and Implementation Strategy Design
Depression screening and treatment program provided at both sites.
In both study arms, a depression screening and treatment program is being integrated into routine NCD care. This integration is being supported by the IC-only model in half of the clinics and by the IC+EQAC model in the other half. The depression screening and treatment program at all sites consists of the components described in the following.
Training.
Given empirical support for a “train the trainers” model (27), we trained three clinicians from each site as ICs, a role that includes training their colleagues. These trainers then trained all NCD care providers (clinical officers and nurses) at their facilities in administrating and scoring the PHQ-9 and using the ABCD to screen for suicidal thoughts, antidepressant management, and follow-up treatment decisions. NCD care providers at participating sites include nurses who handle vital signs monitoring and weight assessment and conduct health talks, and one or more clinical officers handle patient consultations and have prescribing authority. Both groups have received a brief orientation to mental health issues, primarily serious mental illness, as part of their nursing or medical training but have not received specialized mental health training.
In addition, five or six peer NCD patients at each site have been trained in the Friendship Bench intervention, which is designed for low-resource settings (11) and which we have previously adapted for use in Malawi (28). The team of Dr. Chibanda, who helped develop Friendship Bench, trained a group of Malawian trainers, who have now trained these peer patients as counselors. Two counselors who were the top performers at each site as determined by their Malawian trainers were identified as local peer supervisors.
Clinical care.
All patients presenting for care at participating NCD clinics will be given a PHQ-9 sheet at registration along with their NCD medical chart (called mastercard). Patients will take the PHQ-9 into the consultation room with a health care worker (either a clinician or nurse) who will complete and score the PHQ-9. Patients with a PHQ-9 score of 0–4 are recommended for no mental health treatment. Patients with a positive screen for the core depression symptoms of low mood or anhedonia (i.e., a score of >0 on the first two items of the PHQ-9, also known as a PHQ-2 score) and with a score of 5–9 are recommended for the Friendship Bench intervention, and patients with a score of ≥10 are recommended for antidepressant initiation. The actual treatment plan is at the clinician’s discretion (patients can both be initiated on antidepressants and referred for counseling). The treatment plan is recorded on a “mental health mastercard” medical chart, which is filed with the PHQ-9 and the NCD mastercard for retrieval at the next visit when the treatment plan is reassessed and adjusted if needed.
Basic implementation package.
The IC-only package consists of identifying a clinical coordinator (internal champion) at each site. This coordinator is an existing onsite NCD clinician and facility NCD coordinator who is responsible for ensuring the smooth integration of the treatment program. One coordinator and two alternates from each site were identified and trained as clinician trainers as described above. These coordinators have the following responsibilities: train all health care workers at the health facility in the depression treatment program (both initial training and as-needed additional training of new arrivals); maintain a log of current health care workers and training status; ensure accurate record-keeping, including numbers of patients screened, of patients with depression, and of those receiving treatment, and conduct follow-up of patients previously started on treatment; lead depression care supervision monthly; supervise Friendship Bench supervisor monthly; ensure NCD clinic coverage; ensure stable antidepressant medication supply; raise implementation challenges with facility leadership; and compile monthly reports to submit to the MOH. The Malawian public health system often uses this basic implementation strategy, including identification of a local coordinator with the aforementioned responsibilities, in the roll out of new health care programs.
Enhanced implementation package.
The IC+EQAC package includes all the elements of the IC package, with the addition of an EQAC that visits each facility on a quarterly basis each year to audit paperwork, review service delivery, and provide feedback and recommendations to the coordinator, the facility leadership, and the MOH. Each EQAC will consist of two to three MOH officials, one Friendship Bench master trainer, and one to two additional staff members for administrative and logistical support. The site visit will last 2 days and will include an initial meeting with the coordinator and facility leadership to discuss successes and challenges, review of record-keeping, and training, supervision, and review of duty logs of clinicians and counselors. It will also include a review of service delivery indicators, completeness of medical charts, and the appropriateness of treatment decisions as recorded on the medical charts. During the visit, clinical flow and delivery of care, including depression screening and treatment plan discussion, will be directly observed. A meeting will be held with all Friendship Bench counselors that will include listening to at least one recorded counseling session and a discussion of successes and challenges. A debrief meeting will be conducted with the coordinator and facility leadership to discuss findings and recommendations, and a written report will be submitted to the facility’s director for health and social welfare, the NCD clinics, and the mental health unit of the MOH.
Measures
Our key measures (Table 2) will allow us to address our hypotheses regarding fidelity, depression remission, and control of hypertension, diabetes, or both. We will monitor these parameters via periodic chart review fidelity measures for ABCD, including the number of completed supervision sessions and the percentages of new patients completing the PHQ-2 (target ≥80%), of PHQ-2–positive screens with the PHQ-9 (target ≥90%), of PHQ-9–positive screens with assessment for depression (target ≥90%), of patients with confirmed depression enrolled in the study who start antidepressant treatment or Friendship Bench counseling (target ≥80%), of follow-up encounters at which the clinical decision follows the algorithm (target ≥80%), and of algorithm divergences for which the reason for divergence is documented (target ≥90%).
| Construct | Measure | Source | Time point |
|---|---|---|---|
| Screening | |||
| Depression screening coverage | Completion of screening with PHQ-2 and PHQ-9 | Clinical logs | Ongoing throughout study period |
| Treatment initiation | |||
| Initiation of counseling or antidepressants | Initiation of counseling or antidepressants within 30 days of depression identification | Clinical logs | Ongoing throughout study period |
| Fidelity | |||
| Friendship Bench counseling fidelity | Number of sessions attended; counselor fidelity to problem-solving therapy core components | Clinical logs; review of audio-recorded sessions | Ongoing throughout study period |
| Antidepressant dosing algorithm fidelity | Initial antidepressant dose; reassessment at follow-up appointments; treatment adjustment per algorithm at follow-up | Clinical logs | Ongoing throughout study period |
| Clinical outcome | |||
| Depression remission | PHQ-9 | Research interview | At 3, 6, 12 months |
| Hypertension control | Blood pressure | Research interview | At 3, 6, 12 months |
| Diabetes control | Fasting blood glucose | Clinical records | At 6 months |
a
PHQ-2, Patient Health Questionnaire–2; PHQ-9, Patient Health Questionnaire–9.
Fidelity to Friendship Bench will be assessed through the domains of number of sessions delivered and received and adherence to counseling components. We will measure number of sessions delivered with process data indicating the number of sessions made available to participants by their counselors. Similarly, we will measure sessions received as the number of sessions that participants actually attend. Adherence to the intervention protocol will be measured with the Friendship Bench fidelity checklist, which rates a counselor’s adherence to core Friendship Bench counseling components by assessors’ listening to an audio recording of a counselor’s session. All sessions for which the client consents to recording will be recorded, and 10% of recordings per counselor, selected at random, will be reviewed and rated for fidelity during the course of the trial.
Depression remission will be defined as a PHQ-9 score <5, a score widely used and validated (29). Depression response, a common secondary indicator of treatment effectiveness, will be defined as a ≥50% decrease in the PHQ-9 score from that recorded at enrollment (29). Depression-free days is a cumulative measure of burden of depression over time calculated, according to a previously published algorithm (30–32), by translating depressive severity measures at the beginning and end of each time interval into the proportion of days spent depressed. Hypertension and diabetes outcomes will be measured at 0, 6, and 12 months by trained study data collectors recording the data on a tablet and submitting it electronically for storage and later analysis.
Analysis Strategy
Analysis of primary and secondary outcomes will be intent-to-treat comparisons between the two study arms (Table 2). These comparisons will be made with generalized linear regression models with a log link and binomial error distribution to compare individual-level or appointment-level probabilities. Outcomes (see below) will be measured at baseline and at 3, 6, and 12 months.
Primary outcomes: implementation outcomes (fidelity to intervention).
The study will evaluate three primary outcomes (Table 3). The first is the probability that each patient eligible for depression screening completes the screening. We define this outcome as completing the PHQ-2, and, if the PHQ-2 score is >0, also completing the PHQ-9. The second outcome is the probability that each patient eligible for depression treatment starts the treatment within 30 days of diagnosis. We define eligibility for depression treatment as a PHQ-9 total score of ≥5 and a final determination by the treating clinician that the patient is appropriate for depression treatment. The third primary outcome is the probability at each follow-up appointment in the first 3 months of depression treatment that the clinical treatment decision follows the depression treatment guidelines.
| Outcome | Definition |
|---|---|
| Primary | |
| Fidelity in depression screening | Probability that each patient eligible for depression screening completes depression screening |
| Fidelity in depression treatment initiation | Probability that each patient eligible for depression treatment actually starts treatment within 30 days of identificationb |
| Fidelity in follow-up depression treatment monitoring and adjustment | Probability at each follow-up appointment in the first 3 months of depression treatment that the clinical treatment decision follows the depression treatment guidelines |
| Secondary | |
| Probability that each patient achieves depression remission at 3 months | Depression remission is defined as a Patient Health Questionnaire–9 score <5 at 3 months |
| Probability that each patient’s noncommunicable disease (NCD) is well controlled at 3 monthsc | Well-controlled NCD will be defined for hypertension patients as systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, and for diabetes patients as fasting blood glucose <130 mg/dl, following the Malawi clinical guidelines for NCD management |
a
All outcome types were binary.
b
Patients are eligible for depression treatment if they have a Patient Health Questionnaire–9 total score of ≥5 and when the treating clinician determines that a patient can receive depression treatment.
c
Hypertension is measured by research assistants at each study visit, and fasting blood glucose level is measured as part of routine clinical care and will be abstracted from the medical record.
For these three primary fidelity outcomes, where depression screening and treatment actions are clustered within provider and clinic, the analysis will consist of a robust variance estimate clustered by provider and clinic.
Secondary outcomes: effectiveness outcomes (patient health).
Two secondary outcomes will be considered. The first is the probability that each patient achieves depression remission at 3 months. The second is the probability that each patient’s NCD is well controlled at 3 months. For the secondary patient-level effectiveness outcomes, the design effect introduced by clinic-level randomization will be addressed with a robust variance estimate clustered by clinic.
Supplemental analyses.
Planned supplemental analyses will consider patients with hypertension and diabetes separately and consider patients with uncontrolled versus well-controlled baseline NCD separately. Subgroup analyses will be conducted with regression models fit with and without an interaction term(s) between intervention arm and the stratifying variable.
Sample size calculations will be based on two-tailed statistical significance tests, a type I error probability (α) of 0.05, and desired power (1–β) of 0.80. The fidelity outcomes are considered event-specific probabilities. Events (depression screening, treatment initiation, and follow-up action) are nested within providers, who are nested within clinics, the unit of randomization. Assuming a moderately high within-provider correlation (intracluster correlation coefficient [ICC]=0.5) and a lower across-provider-within-clinic correlation (ICC=0.1), and given the large number of providers per clinic, the combination of provider- and clinic-level design effects will yield an effective sample size of N=92 for the primary outcomes. This effective sample size will confer 80% power to detect absolute improvements (risk differences) of 18–27 percentage points in the fidelity outcomes, depending on the outcome frequency (risk) in the comparison arm.
Patient-level outcomes (e.g., depression remission) are patient-specific probabilities that are nested within clinics but not within providers (patients frequently do not see the same provider across visits). Assuming a low intracluster correlation in this patient outcome (ICC=0.02), as has been observed in similar studies (33–36), our sample of 1,160 patients across 10 clinics is equivalent, after accounting for the clinic-level design effect, to an effective sample size of N=352. Assuming 90% retention at 3 months (in line with very high retention rates achieved in many previous large multisite trials by University of North Carolina Project–Malawi) (37, 38), this sample confers 80% power to detect an absolute improvement (risk difference) of 11–15 percentage points in the patient-level outcomes, depending on the outcome frequency (risk) in the comparison arm.
The need for adjusted analyses will be evaluated by comparing the characteristics of participants enrolled in the two arms. Although constrained randomization is expected to yield clinics with approximately balanced characteristics between the arms, clinics in one arm may have more effective screening and therefore may identify different types of patients with depression; thus, patient characteristics might not be balanced between the arms. We will evaluate balance between arms in demographic (age, sex), NCD (hypertension vs. diabetes, controlled vs. uncontrolled) and mental health characteristics (depressive symptom severity, anxiety symptoms, posttraumatic stress disorder symptoms, and alcohol use). We will assess potential confounding by comparing the unadjusted primary analysis to an analysis controlling for potential confounders. Both unadjusted and adjusted results will be presented.
Cost-effectiveness analyses.
We will estimate and compare the average and total costs of the IC-only and IC+EQAC interventions, and the incremental cost per additional case of remitted depression at 3 months of IC+EQAC relative to IC only. These health and economic impact data will inform stakeholders about the sustainability, value for money, and opportunities for efficiency gains of the two interventions. We will measure nonresearch costs of the intervention by using globally accepted best practices. Costs will be captured throughout the trial, and we will measure total delivery costs of each approach deterministically (39). We will use probabilistic sensitivity analysis to account for stochastic uncertainty and use league tables to display results (40).
Trial Status and Timeline
We launched this trial in May 2019. We are planning for 24 months of recruitment (through spring 2021) and 12 months of follow-up (through spring 2022).
Results
The trial will generate critical knowledge to inform policy makers, administrators, and clinicians on which strategies may be more effective at implementing and sustaining standard evidence-based depression screening and management approaches in busy community NCD clinics with limited resources. With fidelity, depression remission, and control of hypertension or diabetes as the main outcomes, along with an assessment of the cost-effectiveness of the interventions, stakeholders will be able to use evidence to inform selection and implementation of depression management packages. Various scenarios can be envisioned. For example, should each package implement and sustain depression screening and management with fidelity and with few differences in clinical outcomes, stakeholders would likely opt for the basic IC-only package. Should both be implemented with fidelity, but the IC+EQAC version produces better clinical outcomes, stakeholders could discuss whether the increased benefit is worth the increased cost. In any case, meaningful information will be created to help stakeholders make a well-informed decision.
Other key results will evolve from the project’s capacity-building efforts. As part of the overall SHARP project, which involves trainees in both Malawi and Tanzania, we will train young researchers to design, implement, and analyze studies of how to implement evidence-based mental health interventions in low-resource settings. Small grant opportunities will allow them to propose their own pilot projects and to participate in the current study. Further, we are partnering with another global mental health hub, Scaling-Up Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence-Based Practices in Mozambique (PRIDE) (41), to jointly mentor other young investigators from their hub for related projects in Malawi and Tanzania.
Next Steps
The Malawi and Tanzania MOHs both strongly support the design of the proposed scale-up study because of the perceived high value and relevance of the proposed depression treatment approach to the mental health agendas in both countries and the importance of identifying the most therapeutically effective and cost-effective strategies for integrating depression screening and management into NCD care. Integration of antidepressants and psychosocial counseling into existing NCD care is viewed as an important component of an overall mental health response because the high prevalence of depression and limited availability of clinical providers in Malawi necessitate an efficient, low-cost approach. The Malawi MOH supports our design and views it as scalable and sustainable within the Malawi health care system. The study is seen as a logical next step of ongoing MOH efforts to expand access to depression management and as an important complement to other efforts to expand counseling capacity. Should these findings reveal benefits in such resource-limited settings as in Malawi, we believe these findings will be generalizable to other countries in sub-Saharan Africa.
On its completion, this scale-up study will provide key information to guide the Malawi MOH in furthering its intention of scaling up ABCD in existing chronic disease care settings. In collaboration with the MOHs and other SHARP partners, we will use the study results as the basis for drafting a detailed revision to the national Mental Health Action Plans in Malawi and Tanzania. Further, the execution of this study will offer SHARP mentees the opportunity to gain invaluable experience in mental health–related implementation science research by participating in the design and conduct of specific aspects and procedures of the study under the mentorship of senior investigators. Overall, this component of the SHARP U19 application to the National Institute of Mental Health will substantially contribute to the SHARP goal of enhancing research capacity in both mental health treatment and implementation science in Malawi and Tanzania.
References
1.
Lopez AD, Mathers CD, Ezzati M, et al : Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 ; 367 : 1747 – 1757
2.
Kessler RC, Aguilar-Gaxiola S, Alonso J, et al : The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009 ; 18 : 23 – 33
3.
Demyttenaere K, Bruffaerts R, Posada-Villa J, et al : Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004 ; 291 : 2581 – 2590
4.
Meeting Report on Excess Mortality in Persons With Severe Mental Disorders. Geneva, World Health Organization, 2015. https://www.who.int/mental_health/evidence/excess_mortality_meeting_report.pdf
5.
Moussavi S, Chatterji S, Verdes E, et al : Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007 ; 370 : 851 – 858
6.
Prince M, Patel V, Saxena S, et al : No health without mental health. Lancet 2007 ; 370 : 859 – 877
7.
Raviola G, Becker AE, Farmer P : A global scope for global health—including mental health. Lancet 2011 ; 378 : 1613 – 1615
8.
Mental Health Atlas 2011. Geneva, World Health Organization, 2011. https://apps.who.int/iris/bitstream/handle/10665/44697/9799241564359_eng.pdf;jsessionid=EA05CC9CD3FF1690C070752F8729F2CF?sequence=1. Accessed Oct 8, 2020
9.
Mental Health Atlas 2005. Geneva, World Health Organization, 2005. https://www.who.int/mental_health/evidence/atlas/global_results.pdf
10.
mhGAP—Mental Health Gap Action Programme: Scaling Up Care for Mental, Neurological and Substance Use Disorders. Geneva, World Health Organization, 2008. https://www.who.int/mental_health/mhgap_final_english.pdf
11.
Chibanda D, Weiss HA, Verhey R, et al : Effect of a primary care-based psychological intervention on symptoms of common mental disorders in Zimbabwe: a randomized clinical trial. JAMA 2016 ; 316 : 2618 – 2626
12.
Chibanda D, Mesu P, Kajawu L, et al : Problem-solving therapy for depression and common mental disorders in Zimbabwe: piloting a task-shifting primary mental health care intervention in a population with a high prevalence of people living with HIV. BMC Public Health 2011 ; 11 : 828
13.
Gaynes BN, Rush AJ, Trivedi MH, et al : Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med 2008 ; 23 : 551 – 560
14.
Landis SE, Gaynes BN, Morrissey JP, et al : Generalist care managers for the treatment of depressed Medicaid patients in North Carolina: a pilot study. BMC Fam Pract 2007 ; 8 : 7
15.
Adams JL, Gaynes BN, McGuinness T, et al : Treating depression within the HIV “medical home”: a guided algorithm for antidepressant management by HIV clinicians. AIDS Patient Care STDS 2012 ; 26 : 647 – 654
16.
Pence BW, Gaynes BN, Atashili J, et al : Feasibility, safety, acceptability, and preliminary efficacy of measurement-based care depression treatment for HIV patients in Bamenda, Cameroon. AIDS Behav 2014 ; 18 : 1142 – 1151
17.
Wagner GJ, Ngo V, Goutam P, et al : A structured protocol model of depression care versus clinical acumen: a cluster randomized trial of the effects on depression screening, diagnostic evaluation, and treatment uptake in Ugandan HIV clinics. PLoS One 2016 ; 11 : e0153132
18.
Katon W, Guico-Pabia CJ : Improving quality of depression care using organized systems of care: a review of the literature. Prim Care Companion CNS Disord 2011 ; 13 : PCC.10r01019blu
19.
Katon WJ, Lin EH, Von Korff M, et al : Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010 ; 363 : 2611 – 2620
20.
Government of the Republic of Malawi Health Sector Strategic Plan II 2017–2022, towards universal health coverage ; in Ministry of Health Malawi Government, 2nd ed. Zomba, Malawi, National Statistics Office, 2017
21.
National Mental Health Policy. Lilongwe, Malawi, Government of Malawi Ministry of Health, 2019
22.
Kilbourne AM, Abraham KM, Goodrich DE, et al : Cluster randomized adaptive implementation trial comparing a standard versus enhanced implementation intervention to improve uptake of an effective re-engagement program for patients with serious mental illness. Implement Sci 2013 ; 8 : 136
23.
Kilbourne AM, Goodrich DE, Lai Z, et al : Reengaging veterans with serious mental illness into care: preliminary results from a national randomized trial. Psychiatr Serv 2015 ; 66 : 90 – 93
24.
Kilbourne AM, Goodrich DE, Nord KM, et al : Long-term clinical outcomes from a randomized controlled trial of two implementation strategies to promote collaborative care attendance in community practices. Adm Policy Ment Health Ment Health Serv Res 2015 ; 42 : 642 – 653
25.
Spitzer RL, Kroenke K, Williams JB : Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 1999 ; 282 : 1737 – 1744
26.
Udedi M, Muula AS, Stewart RC, et al : The validity of the Patient Health Questionnaire–9 to screen for depression in patients with type-2 diabetes mellitus in non-communicable diseases clinics in Malawi. BMC Psychiatry 2019 ; 19 : 81
27.
Martino S, Ball SA, Nich C, et al : Teaching community program clinicians motivational interviewing using expert and train-the-trainer strategies. Addiction 2011 ; 106 : 428 – 441
28.
Stockton MA, Udedi M, Kulisewa K, et al : The impact of an integrated depression and HIV treatment program on mental health and HIV care outcomes among people newly initiating antiretroviral therapy in Malawi. PLoS One 2020 ; 15 : e0231872
29.
Löwe B, Unützer J, Callahan CM, et al : Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 2004 ; 42 : 1194 – 1201
30.
Pyne JM, Tripathi S, Williams DK, et al : Depression-free day to utility-weighted score: is it valid? Med Care 2007 ; 45 : 357 – 362
31.
Lave JR, Frank RG, Schulberg HC, et al : Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998 ; 55 : 645 – 651
32.
Pence BW, Gaynes BN, Adams JL, et al : The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. AIDS 2015 ; 29 : 1975 – 1986
33.
Pals SL, Beaty BL, Posner SF, et al : Estimates of intraclass correlation for variables related to behavioral HIV/STD prevention in a predominantly African American and Hispanic sample of young women. Health Educ Behav 2009 ; 36 : 182 – 194
34.
Parker DR, Evangelou E, Eaton CB : Intraclass correlation coefficients for cluster randomized trials in primary care: the cholesterol education and research trial (CEART). Contemp Clin Trials 2005 ; 26 : 260 – 267
35.
Smeeth L, Ng ES : Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Control Clin Trials 2002 ; 23 : 409 – 421
36.
Eldridge SM, Ashby D, Feder GS, et al : Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials 2004 ; 1 : 80 – 90
37.
Cohen MS, Chen YQ, McCauley M, et al : Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016 ; 375 : 830 – 839
38.
Campbell TB, Smeaton LM, Kumarasamy N, et al : Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012 ; 9 : e1001290
39.
Drummond MF, Sculpher MJ, Torrance GW, et al : Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press, 2005
40.
Tan-Torres Edejer T, Baltussen R, Adam T, et al : Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva, World Health Organization, 2003
41.
Wainberg M : Scaling up PRIDE Mozambique—Scaling up Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence Based Practices in Mozambique. Bethesda, MD, National Institutes of Health, 2017 https://grantome.com/grant/NIH/U19-MH113203-01-7036
Information & Authors
Information
Published In
History
Received: 3 January 2020
Revision received: 2 September 2020
Accepted: 18 September 2020
Published online: 9 December 2020
Published in print: July 01, 2021
Keywords
Authors
Competing Interests
The authors report no financial relationships with commercial interests.
Funding Information
The National Institute of Mental Health (NIMH) funded this project (grant U19-MH-113202-01). This article is part of a series of protocols of NIMH-funded U19s focused on Global Mental Health Implementation Science. ClinicalTrials.gov ID: NCT03711786.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).